	US 12,011,424 B2
	Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
Uchenna H Iloeje, Stamford, CT (US); Abraham J Langseth, Stamford, CT (US); and Todd Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics Inc., Stamford, CT (US)
Filed on Jul. 24, 2023, as Appl. No. 18/357,988.
Application 18/357,988 is a continuation of application No. 18/185,080, filed on Mar. 16, 2023, granted, now 11,819,487.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2024/0058282 A1, Feb. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/166 (2006.01); A61K 9/00 (2006.01); A61K 31/216 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61K 31/216 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)]

6 Claims

1. A method of treating a pediatric human patient 2 to 10 years of age who has neurofibromatosis type 1 NF1) associated inoperable plexiform neurofibromas (PN) comprising orally administering to the patient 1 mg mirdametinib twice daily.